Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer
- 1 June 2004
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (11), 3919-3926
- https://doi.org/10.1158/1078-0432.ccr-03-0787
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- The Myth of Measurable Disease in Ovarian CancerJournal of Clinical Oncology, 2003
- Calculation of the Risk of Ovarian Cancer From Serial CA-125 Values for Preclinical Detection in Postmenopausal WomenJournal of Clinical Oncology, 2003
- Part I: Chemotherapy for epithelial ovarian cancer–treatment at first diagnosisThe Lancet Oncology, 2002
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Phase II trials of docetaxel (taxotere®) in advanced ovarian cancer—an updated overviewEuropean Journal Of Cancer, 1997
- CA 125: A valid marker in ovarian carcinoma patients treated with paclitaxel?Cancer, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983
- Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramideJournal of Chronic Diseases, 1960